Background-Increased production of
non-immune rabbit IgG, TGF-fl2 antibody, or a combination of TGF-Ih and TGF-8,1 antibodies at various dose regimens. Mice were killed 14 days after the instillation and their lungs processed for morphological and biochemical studies.
Results-Administration of 250 pg of TGF-fl2 antibody after instillation of bleomycin followed by 100 ug on day 5 and 100 jg on day 9 significantly reduced the bleomycin induced increases in the accumulation of lung collagen from 445 8 (42. 3) pgllung to 336-7 (56.6) pgllung at 14 days. Similarly, the combined treatment with 250 pug TGF-62 antibody and 250 pg TGF-,61 antibody after bleomycin instillation followed by 100 pg of each antibody on day 5 also caused a significant reduction in bleomycin induced increases in lung collagen accumulation and myeloperoxidase activity at 14 days. Conclusions-These results suggest that TGF-fi has an important role in the aetiology of bleomycin induced lung fibrosis; the neutralisation of TGF-I8 by systemic treatment with its antibodies offers a new mode of pharmacological intervention which may be useful in treating lung fibrosis.
(Thorax 1993;48:959-966)
Interstitial pulmonary fibrosis is a potentially lethal, chronic response of the lung to injury that may result from a wide range of processes.' Regardless of its multifactorial origin, interstitial pulmonary fibrosis is invariably accompanied by an over exuberant repair process, which is characterised by an excessive number of fibroblasts,' an absolute increase in lung collagen content, and abnormality in the ultrastructural appearance and spatial distribution of collagen types. 3 Bleomycin represents a group of glycopeptides that are used as chemotherapy in the treatment of cancer. 4 The use of bleomycin as an antineoplastic drug is, however, limited because it produces a dose dependent pneumonitis which often progresses to interstitial pulmonary fibrosis in humans. 4 Intratracheal instillation of bleomycin in rodents is often used as an animal model of interstitial pulmonary fibrosis as it resembles that seen in humans.5 6 The number of cytokines known to upregulate the inflammatory and fibroproliferative responses of lungs leading to increased extracellular matrix production in the rodent bleomycin model of lung fibrosis is ever increasing.7-10 It is generally accepted that the increased production of transforming growth factor ,B (TGF-ff) is an important component in the pathophysiology of bleomycin induced lung fibrosis for the following reasons. Firstly, TGF-fl is a potent stimulator of extracellular matrix synthesis, although its effects on cell proliferation depend on the presence of other growth factors and culture conditions. [11] [12] [13] Secondly, Raghu et al found that TGF-fl caused a twofold to fourfold increase in collagen production and collagen mRNA in fibroblasts cultured from normal and fibrotic human lungs.'4 Thirdly, there is increased expression of TGF-fl gene and cell proliferation in lungs undergoing bleomycin induced pulmonary fibrosis.'0 1516
In addition, Brockelmann et al found an abundant expression of TGF-f,i mRNA in alveolar macrophages in lung tissue from patients with idiopathic pulmonary fibrosis. '7 These investigators postulated that TGF-fl associated with the extracellular matrix of lung may provide a potent stimulus for the persistent expression of connective tissue genes followed by increased synthesis and deposition of collagen in lung, a hallmark of pulmonary fibrosis. Similarly, Khalil et al found a noticeable and consistent increase in TGF-# production in epithelial cells and macrophages in sections of lung from patients with advanced idiopathic pulmonary fibroSiS. 18 We investigated the role of TGF-# in the pathogenesis of bleomycin induced lung fibrosis by treatment with TGF-fl, antibody or a combination of TGF-fl, and TGF-f,B antibodies at various dose regimens. We also investigated the effects of combined treatment with TGF-fl, and TGF-fl, antibodies on bleomycin induced increases in the lung myeloperoxidase and prolyl hydroxylase activities and lipid peroxidation as well as protein content and acid phosphatase activity of supematant from bronchoalveolar lavage fluid. (3) bleomycin and TGF-f,h antibody (BL + TGF-f), Ab); and (4) bleomycin and TGF-I,h and TGF-I,h antibodies (BL + TGF-/,h + TGF-fJ, Ab). Bleomycin sulphate was freshly dissolved in sterile isotonic saline and TGF-,B antibodies in phosphate buffered saline (sodium dihydrogen phosphate 10 mmol/l in 0-9% saline, pH 7 2) and filtered (0-2 pm filter). The rabbit IgG was also dissolved in phosphate buffered saline and filtered in the same way. Mice were killed either at 8 days or 14 days by an overdose of intraperitoneal pentobarbital (120-130 mg/kg) after intratracheal instillation of saline or bleomycin. The lungs from mice killed at 8 days were used only for measurement of hydroxyproline as an index of collagen accumulation, whereas lungs from mice killed at 14 days were used for analysis of bronchoalveolar lavage fluid and for morphological and biochemical studies.
Methods

BRONCHOALVEOLAR LAVAGE
Lung lavage was performed as previously described.20 Briefly, after cannulation of the trachea the lungs were lavaged with 5 ml of isotonic saline, given in five aliquots of 1 ml. The saline was administered with a syringe through the cannula, the chest wall was gently massaged, and the fluid was withdrawn. The volume of the recovered fluid was measured in a graduated test tube and ranged from 70% to 96% of the total volume with a mean (SD) of 88% (9%). The fluid was centrifuged at 1500 g for 20 minutes at 4°C. The resulting supernatant was collected and stored at -20°C until measurement of protein content and acid phosphatase activity.
PREPARATION OF LUNGS FOR HISTOPATHOLOGY
After lung lavage the thoracic cavity was opened and the heart and lungs were removed en bloc from the thoracic cavity. The lungs were fixed through the trachea at a pressure of 30 To assay hydroxyproline concentration 0-125 ml of 50% cold trichloroacetic acid was added to 0 5 ml of homogenate. After 20 minutes on ice samples were centrifuged, the supernatant discarded, and the precipitate hydrolysed in 1 ml of hydrochloric acid 6 mol/l, overnight (18-20 hours) at 1 10°C. To monitor recovery tritiated hydroxyproline (1.5 x 105 dpm) was added to each hydrolysed sample. The hydroxyproline content of the sample was measured by the technique of Woessner." The recovery of tritiated hydroxyproline ranged from 85% to 95%, and it was used to correct the amount of hydroxyproline for each sample.
MYELOPEROXIDASE ASSAY
The myeloperoxidase activity of the lung homogenate was assayed according to the technique described by Goldblum et al. 23 Myeloperoxidase was extracted in 0 5% hexadecyltrimethylammonium bromide in phosphate buffer 50 mmol/l (pH 6-0). The samples were freeze thawed (20 minutes at -70°C) three times followed by homogenisation each time on ice with a Polytron. The homogenate was then centrifuged at 40 000 g for 15 minutes and the resulting supernatant used to assay for the myeloperoxidase activity spectrophotometrically: 0-1 ml of the supernatant was mixed with 2-9 ml of phosphate buffer 50 mmol/l (pH 6&0) containing 0-dianisidine dihydrochloride 0-167 mg/ml and 0 0005% hydrogen peroxide in a final volume of 3 ml. The change in absorbance at 460 nm was recorded on a Varian 219 Cary spectrophotometer (Varian Instrument Group, Sugarland, Texas). One unit of myeloperoxidase activity was defined as the volume of supernatant that degraded 1 The method for prolyl hydroxylase assay was essentially the same as described by Hutton et al. 25 The incubation mixture for the assay in a total volume of 2 ml consisted of ferrous ammonium sulphate (0-1 mmol/l), a-ketoglutaric acid (0 1 mmol/l), [ 'H]proline procollagen (100 000 dpm), lung homogenate (100,ul), ascorbic acid (0-5 mmol/l), and TRIS-hydrochloric acid buffer (0p 1 mol/l, pH 7-8). The reaction was started by the addition of ascorbic acid and continued for 30 minutes at 37°C in a Dubnoff metabolic shaker. The reaction was stopped by adding 0-2 ml of 50% trichloroacetic acid. The tritiated water of the reaction system was separated by vacuum distillation of the whole reaction mixture. A 1 0 ml aliquot of tritiated water from each distillation was mixed in 15 ml of Tritosol and counted in a liquid scintillation counter (Beckman Model LS 5801). The counting efficiency of the system was 30-35%. The enzyme assay was conducted under conditions giving linear release of product in relation to the amount of sample used and the time of incubation.
MALONDIALDEHYDE ASSAY
Duplicate aliquots of the whole homogenate were used to measure the steady state value of malondialdehyde as an index of lipid peroxidation according to the procedure described by Ohkawa et al. 26 Briefly, the assay entailed mixing 0-2 ml of homogenate, 0-2 ml of 8-1% sodium dodecyl sulphate, 1-5 ml of 20% acetic acid (adjusted to pH 3-5 with sodium hydroxide), 1-5 ml of 0-8% aqueous solution of thiobarbituric acid, and 0-6 ml of distilled deionised water. The mixture was heated at 95°C for 60 minutes. After cooling 5 ml of n-butanol was added and the mixture was shaken vigorously, followed by centrifugation at 2000 g for 10 minutes. The absorbance of the upper organic layer was read at 532 nm and compared with a standard curve with tetraethoxypropane.
PROTEIN CONTENT AND ACID PHOSPHATASE ASSAY
The protein content of the supematant from bronchoalveolar lavage specimens was determined by the method of Lowry et al with bovine serum albumin as standard. 27 The catalysed release of 4-nitrophenol was monitored spectrophotometrically to estimate acid phosphatase activity in the supematant. 28 Briefly, both volume (0-5 ml) and concentration of the buffer substrate solution (sodium citrate 90 mmol/l, 4-nitrophenyl phosphate 15-2 mmol/l, pH 4.9) were adjusted to compensate for the larger sample volume required (0 5 ml). The remainder of the assay was performed as previously described.28
STATISTICAL ANALYSIS
The data are expressed as total lung contents to avoid the artifactual lowering of the values in bleomycin treated animals caused by the presence of proteins of extrapulmonary origin. 29 ,ug/lung) and bleomycin and TGF-fl,2 antibody (336-7 (56 6) pg/lung) were significantly (p < 0-05) increased to 225% and 170% of the value in the saline and IgG group (197-6 (6 1) pg/lung), respectively. However, the treatment with TGF-fl,2 antibody significantly (p < 0 05) reduced the accumulation of lung collagen caused by intratracheal instillation of bleomycin.
Since treatment with TGF-fl2 antibody alone did not completely block the bleomycin induced increases in lung collagen accumulation, we tested the effect of combined treatment with TGF-I2 and TGF-fl1 antibodies at various dose regimens. In a preliminary study treatment with one dose of TGF-fl2 antibody (100 pg) and TGF-/h1 antibody (100 ,ug) administered via the tail vein within five minutes after intratracheal instillation of bleomycin had no effect on bleomycin induced increases in the lung hydroxyproline content at 14 days. The hydroxyproline contents expressed as mean (SE)(n) were 192-7 (9 6) (8), 350-2 (30 4) (11), and 369-1 (fig 4D) . The The beneficial effect of TGF-Ih and TGF-/l, antibodies in minimising the lung collagen accumulation and the severity and extent of the pulmonary fibrotic lesions depends on the dose and the duration of the study. One single dose of the combined antibodies administered in smaller amount (100 ,ug each) had no effect at 14 days, whereas a higher amount (250 pg each) administered soon after bleomycin and thereafter in a smaller amount (100,pg each) at five days caused a marked reduction in the lung collagen accumulation and the severity and extent of the fibrotic lesions at 14 days but not at 8 days after intratracheal instillation of bleomycin. The lung toxicity of bleomycin is associated with an increased sequestration of neutrophils,35 which is measured by myeloperoxidase activity in the lung23; increased lipid peroxidation, measured by the lung content of malondialdehyde35; increased lung prolyl hydroxylase activity,37 an enzyme responsible for post-translational modification of collagen before its maturation; and increased pulmonary vascular permeability, measured by the amount of extravasated plasma proteins35 and increased acid phosphatase activity35 in the supematant of bronchoalveolar lavage fluid. In our study mice treated with bleomycin and IgG had significantly higher lung myeloperoxidase and prolyl hydroxylase activities and malondialdehyde content and also a higher concentration of protein in the supematant than mice treated with saline and IgG in the control group. These findings are consistent with the earlier findings and support the hypothesis that generation of reactive oxygen species is involved in bleomycin induced lung toxicity.
Other biochemical markers for evaluating the antifibrotic potential of exogenously administered compounds in the rodents with lung fibrosis include lipid peroxidation, prolyl hydroxylase, and myeloperoxidase activities in lungs and protein content and acid phosphatase activity in the superatant of bronchoalveolar lavage fluid.'7 Interestingly, systemic treatment with high doses of TGF-/32 and TGF-/3l antibodies caused an appreciable reduction in lung myeloperoxidase activity 14 days after intratracheal instillation of bleomycin but had only marginal attenuating effect on other biochemical determinants.
This suggests that treatment with these antibodies does not diminish the ability of bleomycin to generate reactive oxygen species.
Myeloperoxidase contains haeme and is primarily present in the azurophilic granules of neutrophils.'8 The activity of this enzyme in the lung is used as an index of intrapulmonary sequestration of neutrophils.3 Several laboratories including our own have shown the sequestration of neutrophils in the lungs of bleomycin treated animals.'5 It has been postulated that excessive accumulation of neutrophils in vascular, interstitial, and alveolar spaces would inflict lung injury by generating reactive oxygen species and releasing proteolytic enzymes and myeloperoxidase."40 Myeloperoxidase released from neutrophils is known to oxidise chloride ions to hypochlorous acid (HOCI) in a reaction with hydrogen peroxide.40 Hypochlorous acid is biocidal as it immediately oxidises biologically important constituents of cells, including carbohydrates, nucleic acids, peptide linkages, and causes depletion of cellular NAD and ATP, leading to cell death.4' Recently, we reported that dermal application of nitroglycerine not only decreased the bleomycin induced increase in lung myeloperoxidase activity but also minimised lung toxicity. 
